360 related articles for article (PubMed ID: 28701190)
41. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?
Hynninen J; Lavonius M; Oksa S; Grénman S; Carpén O; Auranen A
Gynecol Oncol; 2013 Feb; 128(2):229-32. PubMed ID: 23142076
[TBL] [Abstract][Full Text] [Related]
42. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort.
Drews F; Bertelli G; Lutchman-Singh K
Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137
[TBL] [Abstract][Full Text] [Related]
43. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
[TBL] [Abstract][Full Text] [Related]
44. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
45. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.
Greimel E; Kristensen GB; van der Burg ME; Coronado P; Rustin G; del Rio AS; Reed NS; Nordal RR; Coens C; Vergote I;
Gynecol Oncol; 2013 Nov; 131(2):437-44. PubMed ID: 23994107
[TBL] [Abstract][Full Text] [Related]
46. Impact of Neoadjuvant Chemotherapy on the Rate of Bowel Resection in Advanced Epithelial Ovarian Cancer.
Philip CA; Pelissier A; Bonneau C; Hequet D; Rouzier R; Pouget N
Anticancer Res; 2016 Sep; 36(9):4865-71. PubMed ID: 27630342
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
[TBL] [Abstract][Full Text] [Related]
48. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer.
Merlo S; Besic N; Drmota E; Kovacevic N
Radiol Oncol; 2021 Aug; 55(3):341-346. PubMed ID: 33675192
[TBL] [Abstract][Full Text] [Related]
49. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
[TBL] [Abstract][Full Text] [Related]
50. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
[TBL] [Abstract][Full Text] [Related]
51. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
[TBL] [Abstract][Full Text] [Related]
52. A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.
Straubhar AM; Filippova OT; Cowan RA; Lakhman Y; Sarasohn DM; Nikolovski I; Torrisi JM; Ma W; Abu-Rustum NR; Gardner GJ; Sonoda Y; Zivanovic O; Chi DS; Long Roche K
Gynecol Oncol; 2020 Sep; 158(3):608-613. PubMed ID: 32518012
[TBL] [Abstract][Full Text] [Related]
53. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
Worley MJ; Guseh SH; Rauh-Hain JA; Williams KA; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727
[TBL] [Abstract][Full Text] [Related]
54. Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?
Vizzielli G; Fanfani F; Chiantera V; Tortorella L; Lucidi A; Petrillo M; Costantini B; Scambia G; Fagotti A
Anticancer Res; 2015 May; 35(5):3027-32. PubMed ID: 25964591
[TBL] [Abstract][Full Text] [Related]
55. Differences in regional diagnostic strategies and in intended versus actual first-line treatment of patients with advanced ovarian cancer in Denmark.
Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Sogaard CH; Hoegdall C
Int J Gynecol Cancer; 2014 Sep; 24(7):1195-205. PubMed ID: 25101855
[TBL] [Abstract][Full Text] [Related]
56. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
57. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
[TBL] [Abstract][Full Text] [Related]
58. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
[TBL] [Abstract][Full Text] [Related]
60. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
